Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc stock is traded at $67.52, with a volume of 1,716,287. It is down -2.24% in the last 24 hours and down -8.89% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.